Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Rex Fang & Innovation Equity Premium Income ETF (FEPI) vs Novartis AG (NVS) Price & Performance

Rex Fang & Innovation Equity Premium Income ETFTrade
Novartis AGTrade

Price performance (Past 24H)

Key statistics

Rex Fang & Innovation Equity Premium Income ETF vs Novartis AG — how do they compare? Rex Fang & Innovation Equity Premium Income ETF trades at $41.87, while Novartis AG trades at $153.53 (market cap $298.18B). The key difference: Novartis AG pays a 3.02% dividend while Rex Fang & Innovation Equity Premium Income ETF pays none, and Novartis AG is trading nearer its 52-week high, Rex Fang & Innovation Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals.

FEPINVS
Sector
Income / Options OverlayHealth
52-Week High
$49.54$168.62
52-Week Low
$37.98$119.31
Market Cap
$298.18B
Enterprise Value
$339.50B
Dividend Yield
3.02%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Rex Fang & Innovation Equity Premium Income ETF

FEPI trades at $41.78, up 0.8% with a bullish technical signal from moving averages, though oscillators are neutral. The ETF provides a high yield through weekly dividends, recently transitioning to this frequency to enhance income compounding. Support and resistance are tightly clustered around $41-$42, indicating potential near-term consolidation.

Outlook: High income appeals but covered call strategy caps upside and risks NAV erosion in downturns. Opportunities include weekly cash flow for income-focused investors; risks involve concentrated tech exposure and market volatility. Analyst views are mixed, emphasizing accumulation on weakness.

Novartis AG

Novartis (NVS) trades at $156.33, up 1.37% on the day, with a bullish technical signal and strong support near $156. The company reported Q2 2026 earnings that beat expectations, driven by robust oncology drug sales, and reaffirmed full-year guidance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%, while valuation ratios like P/E of 23.61 and P/B of 7.15 reflect premium pricing. Recent news highlights institutional buying and CEO confidence in the growth pipeline.

The outlook for NVS is positive, supported by earnings momentum and a diversified drug portfolio, but risks include generic competition for Entresto and pricing pressures. Analyst consensus is mixed with 24% buy ratings, indicating cautious optimism. Investment appeal hinges on execution of new drug launches and offsetting legacy product declines.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Rex Fang & Innovation Equity Premium Income ETF

FEPI provides exposure to top innovation stocks while generating monthly income. It uses a covered call strategy on high-volatility tech stocks to capture option premiums for investors.

Read more on FEPI

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

Read more on NVS